OncoSELECT - Cancer-Specific Biomarker Test Kit on a Liquid Biopsy
From Diagnostic Tests
OncoSELECT: Smart liquid biopsy panels with selected key genes per tumor type. The Liquid Biopsy Solution For Disease Monitoring Or Therapeutic Decision. OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.
-
Most popular related searches
SAMPLE TYPE: Liquid biopsy
The following stage IV solid tumors in adults:
- Non-small cell lung cancer
- Breast (HR+ and HER2+) cancer
- Colorectal cancer
The added value of ctDNA
IDENTIFY SENSITIVITY/RESISTANCE TO THERAPY
OncoSELECT detects potential sensitivity/resistance to targeted/hormonal therapies by targeting more than 100 mutations associated with treatment response (SNVs, indels, translocations and CNVs) in a cancer-specific manner.
It is recommended for patients whose tissue sample is not available or is limited, when it is challenging or not possible to perform a solid biopsy, or if the biopsy sample is too old.
MONITORING TOOL
OncoSELECT monitors tumour response to targeted/hormonal treatments, detects potential resistance mechanisms and may suggest new treatment options. It is fast, minimally invasive for the patient and more sensitive than routine imaging.
Customer reviews
No reviews were found for OncoSELECT - Cancer-Specific Biomarker Test Kit on a Liquid Biopsy. Be the first to review!